Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 3Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 3Radiation Pneumonitis 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Locally Advanced Cervical Carcinoma 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Carboplatin 67Cisplatin 57Paclitaxel 42Radiotherapy 35Pemetrexed 34Gemcitabine 31Docetaxel 31Etoposide 25pembrolizumab 21Vinorelbine 20Erlotinib Hydrochloride 13Magnetic Resonance Spectroscopy 12Gefitinib 11Specimen Handling 10Radiosurgery 10Drug Therapy 10Bevacizumab 10durvalumab 9Nivolumab 9Vinblastine 6Topotecan 6Surgical Procedures, Operative 6Cyclophosphamide 6atezolizumab 5Standard of Care 5Platinum 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lung Neoplasms × Immunotherapy × Clear all
NCT07135882 2025-08-22

PRIME-Lung

Trans Tasman Radiation Oncology Group

Phase 3 Not yet recruiting
420 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡